SCHEDULE 13G/A: Biotechnology Value Fund and Affiliates Update 8.3% Stake in Ikena Oncology
Schedule 13G Amendment
Biotechnology Value Fund and its affiliated entities, including Mark N. Lampert, have disclosed an updated aggregate beneficial ownership of 8.3% of Ikena Oncology, Inc.'s common stock as of December 31, 2024.
Summary
- Biotechnology Value Fund, L.P. (BVF) and its affiliated entities, including BVF I GP LLC, Biotechnology Value Fund II, L.P. (BVF2), BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, collectively reported their beneficial ownership in Ikena Oncology, Inc.
- As of December 31, 2024, the aggregate beneficial ownership by BVF Partners L.P., BVF Inc., and Mark N. Lampert is 4,006,564 shares, representing approximately 8.3% of Ikena Oncology's outstanding common stock.
- This percentage is calculated based on 48,258,111 shares outstanding as of November 1, 2024, as disclosed in Ikena Oncology's Quarterly Report on Form 10-Q filed on November 7, 2024.
- Individual beneficial ownership stakes include BVF with 2,066,854 shares (4.3%), BVF2 with 1,669,108 shares (3.5%), and Biotechnology Value Trading Fund OS LP with 208,765 shares (0.4%).
- The filing, an Amendment No. 4 to Schedule 13G, certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the company's performance or outlook. It simply updates an investor's stake.
Positives
- A significant institutional investor, Biotechnology Value Fund, maintains a substantial stake (8.3%) in Ikena Oncology, which may be interpreted as a continued vote of confidence in the company's long-term prospects.
Negatives
- The document, being a beneficial ownership report, does not contain any negative information regarding Ikena Oncology's operational performance or financial outlook.
Risks
- This Schedule 13G filing primarily reports beneficial ownership and does not detail specific risks related to Ikena Oncology's business operations, financial health, or future prospects.
Future Outlook
NA
Industry Context
The filing indicates continued investment by a specialized biotechnology fund in Ikena Oncology, a company operating in the oncology sector. This suggests that despite broader market conditions, specialized funds are maintaining or adjusting positions in specific biotech firms.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially signal confidence or lack thereof. The continued significant stake by BVF may be viewed positively by other investors.
Key Dates
| Date | Description |
|---|---|
| 2021-04-05 | Date of the initial Schedule 13G filing by the Reporting Persons, referenced in Item 8. |
| 2024-11-01 | Date as of which the number of outstanding shares (48,258,111) was reported in the Issuer's Form 10-Q. |
| 2024-11-07 | Date Ikena Oncology, Inc. filed its Quarterly Report on Form 10-Q with the SEC, disclosing outstanding shares. |
| 2024-12-31 | Date of event which requires filing of this statement, reflecting the beneficial ownership stake. |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 4. |
Keywords
Ikena Oncology, Biotechnology Value Fund, BVF, Mark N. Lampert, SEC filing, Schedule 13G, Beneficial ownership, Common Stock, Institutional investor, Equity stake, Biotechnology, Oncology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.